Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Bio-Techne turns cytokines, antibodies and spatial-biology instruments into revenue isn鈥檛 easy鈥攊ts regulatory footnotes span hundreds of pages and frequent 8-K lab-equipment updates. If you鈥檝e ever wondered what Bio-Techne reports in their SEC filings or needed Bio-Techne insider trading Form 4 transactions before a material announcement, you know the challenge.
Stock Titan solves it. Our AI-powered summaries turn dense 10-K paragraphs about protein-sciences margins into plain language, flag key figures inside every Bio-Techne annual report 10-K simplified, and surface segment-level R&D spend within each Bio-Techne quarterly earnings report 10-Q filing. AG真人官方-time alerts push Bio-Techne Form 4 insider transactions real-time to your dashboard, while interactive charts make Bio-Techne earnings report filing analysis quick. Get Bio-Techne SEC filings explained simply by our platform.
All filing types are indexed the moment EDGAR releases them, then clarified by experts and AI. Use our tools to:
- Decode Bio-Techne proxy statement executive compensation without searching footnotes
- Monitor Bio-Techne executive stock transactions Form 4 alongside share-based pay details
- See Bio-Techne 8-K material events explained minutes after they post
- Save time understanding Bio-Techne SEC documents with AI instead of scrolling page by page
Whether you鈥檙e comparing reagent-sales trends or assessing acquisition milestones, Stock Titan gives complete coverage鈥�10-Ks, 10-Qs, 8-Ks, S-8s and more鈥攑lus contextual guidance on what each disclosure means for a life-sciences business. Make informed decisions faster and never miss a Bio-Techne insider trading Form 4 transaction again.
T-Mobile US, Inc. (TMUS) 鈥� Form 4 insider transaction. President of the Business Group, Callie R. Field, reported the sale of 12,300 common shares on 07/29/2025 under transaction code 鈥淪.鈥� The weighted-average sale price was $240.80 per share (range: $240.79-$240.87). After the sale, Field directly owns 110,891.114 shares of TMUS common stock. No derivative security activity or Rule 10b5-1 trading plan disclosure was indicated. The filing was signed by Attorney-in-Fact Frederick Williams on 07/31/2025.
The transaction reduces Field鈥檚 direct holdings by roughly 10% versus the pre-sale balance (123,191.114 shares) but leaves a substantial remaining position. No accompanying narrative explains motive or use of proceeds, and there were no other simultaneous insider transactions disclosed.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
What are the primary business segments of Bio-Techne Corporation?
How does Bio-Techne support scientific research?
What distinguishes Bio-Techne in a competitive market?
Who are the main customers of Bio-Techne Corporation?
How does Bio-Techne ensure product quality and reliability?
What role do strategic partnerships play for the company?
Can you describe the global presence of Bio-Techne?
